<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIDAURA- auranofin capsule </strong><br>Prometheus Laboratories Inc.<br></p></div>
<h1>PRESCRIBING INFORMATION <br>RIDAURA<span class="Sup">®</span><br>Auranofin <br>Capsules</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">R<span class="Sub">x</span> Only</p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-2"></a><p></p>
<p class="First">RIDAURA<span class="Sup">®</span> (auranofin) contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hemoglobin, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Therefore, the results of recommended laboratory work (See <a href="#s9">PRECAUTIONS</a>) should be reviewed before writing each RIDAURA prescription. Like other gold preparations, RIDAURA is only indicated for use in selected patients with active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. Physicians planning to use RIDAURA should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of RIDAURA.</p>
<p>In addition, the following precautions should be routinely employed:</p>
<ol class="Arabic">
<li>The possibility of adverse reactions should be explained to patients before starting therapy.</li>
<li>Patients should be advised to report promptly any symptoms suggesting toxicity. (See <a href="#s17">PRECAUTIONS—Information for Patients</a>.)</li>
</ol>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">RIDAURA (auranofin) is available in oral form as capsules containing 3 mg auranofin.</p>
<p>Auranofin is (2,3,4,6-tetra-O-acetyl-1-thio-ß-D-glucopyranosato-S-) (triethyl–phosphine) gold.</p>
<p>Auranofin contains 29% gold and has the following chemical structure:</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&amp;name=rid01-0003-01.jpg">
</div>
<p>Each RIDAURA capsule, with opaque brown cap and opaque tan body, contains auranofin, 3 mg, and is imprinted with the product name RIDAURA. Inactive ingredients consist of benzyl alcohol, cellulose, cetylpyridinium chloride, D&amp;C Red No. 33, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, FD&amp;C Yellow No. 6, gelatin, lactose, magnesium stearate, povidone, sodium lauryl sulfate, sodium starch glycolate, starch, titanium dioxide and trace amounts of other inactive ingredients.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The mechanism of action of RIDAURA (auranofin) is not understood. In patients with adult <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, RIDAURA may modify disease activity as manifested by <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span> and associated symptoms, and reflected by laboratory parameters such as ESR. There is no substantial evidence, however, that gold-containing compounds induce remission of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics:</span> Pharmacokinetic studies were performed in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients, not in normal volunteers. Auranofin is rapidly metabolized and intact auranofin has never been detected in the blood. Thus, studies of the pharmacokinetics of auranofin have involved measurement of gold concentrations. Approximately 25% of the gold in auranofin is absorbed.</p>
<p>The mean terminal plasma half-life of auranofin gold at steady state was 26 days (range 21 to 31 days; n=5). The mean terminal body half-life was 80 days (range 42 to 128; n=5). Approximately 60% of the absorbed gold (15% of the administered dose) from a single dose of auranofin is excreted in urine; the remainder is excreted in the feces.</p>
<p>In clinical studies, steady state blood-gold concentrations are achieved in about three months. In patients on 6 mg auranofin/day, mean steady state blood-gold concentrations were 0.68 ±0.45 mcg/mL (n=63 patients). In blood, approximately 40% of auranofin gold is associated with red cells, and 60% associated with serum proteins. In contrast, 99% of injectable gold is associated with serum proteins.</p>
<p>Mean blood-gold concentrations are proportional to dose; however, no correlation between blood-gold concentrations and safety or efficacy has been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">RIDAURA (auranofin) is indicated in the management of adults with active classical or definite <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies.</p>
<p>Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.</p>
<p>When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span>, particularly in its early stage.</p>
<p>In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">RIDAURA (auranofin) is contraindicated in patients with a history of any of the following gold-induced disorders: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> or other severe hematologic disorders.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Danger signs of possible gold toxicity include <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hemoglobin, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> below 4,000 WBC/cu mm, granulocytes below 1,500/cu mm, decrease in platelets below 150,000/cu mm, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> has occurred in 1–3% of patients (See <a href="#s24">ADVERSE REACTIONS</a>) treated with RIDAURA (auranofin), some of whom developed <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. The <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> usually appears to be peripheral in origin and is usually reversible upon withdrawal of RIDAURA. Its onset bears no relationship to the duration of RIDAURA therapy and its course may be rapid. While patients' platelet counts should normally be monitored at least monthly (See <a href="#s18">PRECAUTIONS— Laboratory Tests</a>), the occurrence of a precipitous decline in platelets or a platelet count less than 100,000/cu mm or signs and symptoms (e.g., <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> or <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>) suggestive of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> indicates a need to immediately withdraw RIDAURA and other therapies with the potential to cause <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and to obtain additional platelet counts. No additional RIDAURA should be given unless the <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> resolves and further studies show it was not due to gold therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> has developed in 3-9% of patients (See <a href="#s24">ADVERSE REACTIONS</a>) treated with RIDAURA. If clinically significant <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> or <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">microscopic hematuria</span> is found (See <a href="#s18">PRECAUTIONS— Laboratory Tests</a>), RIDAURA and other therapies with the potential to cause <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> or <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">microscopic hematuria</span> should be stopped immediately.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> The safety of concomitant use of RIDAURA (auranofin) with injectable gold, hydroxychloroquine, penicillamine, immunosuppressive agents (e.g., cyclophosphamide, azathioprine, or methotrexate) or high doses of corticosteroids has not been established.</p>
<p>Medical problems that might affect the signs or symptoms used to detect RIDAURA toxicity should be under control before starting RIDAURA (auranofin).</p>
<p>The potential benefits of using RIDAURA in patients with progressive <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, significant hepatocellular disease, <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or history of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> should be weighed against 1) the potential risks of gold toxicity on organ systems previously compromised or with decreased reserve, and 2) the difficulty in quickly detecting and correctly attributing the toxic effect.</p>
<p>The following adverse reactions have been reported with the use of gold preparations and require modification of RIDAURA treatment or additional monitoring. See <a href="#s24">ADVERSE REACTIONS</a> for the approximate incidence of those reactions specifically reported with RIDAURA.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal Reactions:</span> Gastrointestinal reactions reported with gold therapy include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. The most common reaction to RIDAURA is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> reported in approximately 50% of the patients. This is generally manageable by reducing the dosage (e.g., from 6 mg daily to 3 mg) and in only 6% of the patients is it necessary to discontinue RIDAURA (auranofin) permanently. <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative enterocolitis</span> is a rare serious gold reaction. Therefore, patients with <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> should be monitored for the appearance of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Bold">Cutaneous Reactions:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span> is the most common reaction to injectable gold therapy and the second most common reaction to RIDAURA. <span class="Italics">Any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>, especially if pruritic, that develops during treatment should be considered a gold reaction until proven otherwise.</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> often exists before <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> becomes apparent, and therefore should be considered to be a warning signal of a cutaneous reaction. Gold <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> may be aggravated by exposure to sunlight or an actinic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may develop. The most serious form of cutaneous reaction reported with injectable gold is <span class="product-label-link" type="condition" conceptid="4135953" conceptname="Chronic generalized exfoliative dermatitis">generalized exfoliative dermatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-7.1.3"></a><p></p>
<p class="First"><span class="Bold">Mucous Membrane Reactions:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, another common gold reaction, may be manifested by shallow <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> on the buccal membranes, on the borders of the tongue, and on the palate or in the pharynx. <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span> may occur as the only adverse reaction or with a <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>. Sometimes diffuse <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span> or <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span> develops. A metallic taste may precede these oral mucous membrane reactions and should be considered a warning signal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-7.1.4"></a><p></p>
<p class="First"><span class="Bold">Renal Reactions:</span> Gold can produce a <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulitis</span> with <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>. These renal reactions are usually relatively mild and subside completely if recognized early and treatment is discontinued. They may become severe and chronic if treatment is continued after the onset of the reaction. Therefore it is important to perform urinalyses regularly and to discontinue treatment promptly if <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> or <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> develops.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-7.1.5"></a><p></p>
<p class="First"><span class="Bold">Hematologic Reactions:</span> <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span> including <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have all been reported as reactions to injectable gold and RIDAURA. These reactions may occur separately or in combination at anytime during treatment. Because they have potentially serious consequences, <span class="Italics"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> should be constantly watched for through regular monitoring (at least monthly) of the formed elements of the blood throughout treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-7.1.6"></a><p></p>
<p class="First"><span class="Bold">Miscellaneous Reactions:</span> Rare reactions attributed to gold include <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; gold <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>; partial or complete <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients should be advised of the possibility of toxicity from RIDAURA and of the signs and symptoms that they should report promptly. (Patient information sheets are available.)</p>
<p>Women of childbearing potential should be warned of the potential risks of RIDAURA therapy during pregnancy (See <a href="#s21">PRECAUTIONS— Pregnancy</a>).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s18"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests:</span> CBC with differential, platelet count, urinalysis, and renal and liver function tests should be performed prior to RIDAURA (auranofin) therapy to establish a baseline and to identify any preexisting conditions.</p>
<p>CBC with differential, platelet count and urinalysis should then be monitored at least monthly; other parameters should be monitored as appropriate.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s19"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> In a single patient-report, there is the suggestion that concurrent administration of RIDAURA and phenytoin may have increased phenytoin blood levels.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s20"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis/Mutagenesis:</span> In a 24-month study in rats, animals treated with auranofin at 0.4, 1.0 or 2.5 mg/kg/day orally (3, 8 or 21 times the human dose) or gold sodium thiomalate at 2 or 6 mg/kg injected twice weekly (4 or 12 times the human dose) were compared to untreated control animals.</p>
<p>There was a significant increase in the frequency of renal tubular cell karyomegaly and cytomegaly and renal <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> in the animals treated with 1.0 or 2.5 mg/kg/day of auranofin and 2 or 6 mg/kg twice weekly of gold sodium thiomalate. Malignant renal epithelial tumors were seen in the 1.0 mg/kg/day and the 2.5 mg/kg/day auranofin and in the 6 mg/kg twice weekly gold sodium thiomalate–treated animals.</p>
<p>In a 12-month study, rats treated with auranofin at 23 mg/kg/day (192 times the human dose) developed tumors of the renal tubular epithelium, whereas those treated with 3.6 mg/ kg/day (30 times the human dose) did not.</p>
<p>In an 18-month study in mice given oral auranofin at doses of 1, 3 and 9 mg/kg/day (8, 24 and 72 times the human dose), there was no statistically significant increase above controls in the instances of tumors.</p>
<p>In the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, auranofin at high concentrations (313 to 700 ng/mL) induced increases in the mutation frequencies in the presence of a rat liver microsomal preparation. Auranofin produced no mutation effects in the Ames test (<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>), in the <span class="Italics">in vitro</span> assay (Forward and Reverse Mutation Inducement Assay with Saccharomyces), in the <span class="Italics">in vitro</span> transformation of BALB/T3 cell mouse assay or in the Dominant Lethal Assay.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s21"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span> Teratogenic Effects— Pregnancy Category C. Use of RIDAURA (auranofin) by pregnant women is not recommended. Furthermore, women of childbearing potential should be warned of the potential risks of RIDAURA therapy during pregnancy. (See below.)</p>
<p>Pregnant rabbits given auranofin at doses of 0.5, 3 or 6 mg/kg/day (4.2 to 50 times the human dose) had impaired food intake, decreased maternal weights, decreased fetal weights and an increase above controls in the incidence of resorptions, abortions and congenital abnormalities, mainly abdominal defects such as <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span> and <span class="product-label-link" type="condition" conceptid="4245842" conceptname="Umbilical hernia">umbilical hernia</span>. Pregnant rats given auranofin at a dose of 5 mg/kg/day (42 times the human dose) had an increase above controls in the incidence of resorptions and a decrease in litter size and weight linked to maternal toxicity. No such effects were found in rats given 2.5 mg/kg/day (21 times the human dose).</p>
<p>Pregnant mice given auranofin at a dose of 5 mg/kg/day (42 times the human dose) had no teratogenic effects.</p>
<p>There are no adequate and well-controlled RIDAURA studies in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s22"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Nursing during RIDAURA therapy is not recommended.</p>
<p>Following auranofin administration to rats and mice, gold is excreted in milk. Following the administration of injectable gold, gold appears in the milk of nursing women; human data on auranofin are not available.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s23"></a><a name="section-7.8"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> RIDAURA (auranofin) is not recommended for use in pediatric patients because its safety and effectiveness have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s24"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions incidences listed below are based on observations of 1) 4,784 RIDAURA treated patients in clinical trials (2,474 U.S., 2,310 foreign), of whom 2,729 were treated more than one year and 573 for more than three years; and 2) postmarketing experience. The highest incidence is during the first six months of treatment; however, reactions can occur after many months of therapy. With rare exceptions, all patients were on concomitant nonsteroidal anti-inflammatory therapy; some of them were also taking low dosages of corticosteroids.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-8.1"></a><p></p>
<h2>Reactions occurring in more than 1% of RIDAURA-treated patients</h2>
<p class="First"><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (47%); <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (14%); <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (10%); <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>; <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>*; <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>*; <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>*; <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>.</p>
<p><span class="Bold">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (24%); <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (17%); <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p><span class="Bold">Mucous Membrane:</span> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (13%); <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>*; <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>.</p>
<p><span class="Bold">Hematological:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Bold">Renal:</span> <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>*; <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>.</p>
<p><span class="Bold">Hepatic:</span> elevated liver enzymes.</p>
<p>*Reactions marked with an asterisk occurred in 3-9% of the patients. The other reactions listed occurred in 1-3%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-8.2"></a><p></p>
<h2>Reactions occurring in less than 1% of RIDAURA-treated patients</h2>
<p class="First"><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>; gastrointestinal bleeding†; melena†; positive stool for occult blood†; <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative enterocolitis</span>.</p>
<p><span class="Bold">Dermatological:</span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Mucous Membrane:</span> gingivitis†.</p>
<p><span class="Bold">Hematological:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>; neutropenia†; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>; <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p><span class="Bold">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>.</p>
<p><span class="Bold">Neurological:</span> <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<p><span class="Bold">Ocular:</span> gold deposits in the lens or cornea unassociated clinically with <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorders</span> or <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>.</p>
<p>† Reactions marked with a dagger occurred in 0.1-1% of the patients. The other reactions listed occurred in less than 0.1%.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s27"></a><a name="section-8.3"></a><p></p>
<h2>Reactions reported with injectable gold preparations, but not with RIDAURA (auranofin) (based on clinical trials and on postmarketing experience)</h2>
<p class="First"><span class="Bold">Cutaneous Reactions:</span> <span class="product-label-link" type="condition" conceptid="4135953" conceptname="Chronic generalized exfoliative dermatitis">generalized exfoliative dermatitis</span>.</p>
<a name="t300"></a><table width="100%">
<caption><span> Incidence of Adverse Reactions for Specific Categories—18 Comparative Trials</span></caption>
<col align="left" width="39.200%">
<col align="left" width="30.400%">
<col align="left" width="30.400%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" valign="top">RIDAURA<br>(445 patients)</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Injectable Gold<br>(445 patients)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td align="center" valign="top">0.9%</td>
<td class="Rrule" align="center" valign="top">5.4%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">26%</td>
<td class="Rrule" align="center" valign="top">39%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">42.5%</td>
<td class="Rrule" align="center" valign="top">13%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td align="center" valign="top">13%</td>
<td class="Rrule" align="center" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center" valign="top">3.1%</td>
<td class="Rrule" align="center" valign="top">2.7%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td align="center" valign="top">1.3%</td>
<td class="Rrule" align="center" valign="top">2.2%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center" valign="top">0.9%</td>
<td class="Rrule" align="center" valign="top">2.2%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Elevated liver</td>
<td align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">  function tests</td>
<td align="center" valign="top">1.9%</td>
<td class="Rrule" align="center" valign="top">1.7%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">Pulmonary</td>
<td class="Botrule" align="center" valign="top">0.2%</td>
<td class="Botrule Rrule" align="center" valign="top">0.2%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s28"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The acute oral LD50 for auranofin is 310 mg/kg in adult mice and 265 mg/ kg in adult rats. The minimum lethal dose in rats is 30 mg/kg.</p>
<p>In case of acute overdosage, immediate induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage and appropriate supportive therapy are recommended.</p>
<p>
							RIDAURA overdosage experience is limited. A 50-year-old female, previously on 6 mg RIDAURA daily, took 27 mg (9 capsules) daily for 10 days and developed an <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. RIDAURA was discontinued and she eventually recovered.</p>
<p>There has been no experience with treating RIDAURA overdosage with modalities such as chelating agents. However, they have been used with injectable gold and may be considered for RIDAURA overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s29"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Usual Adult Dosage:</span> The usual adult dosage of RIDAURA (auranofin) is 6 mg daily, given either as 3 mg twice daily or 6 mg once daily. Initiation of therapy at dosages exceeding 6 mg daily is not recommended because it is associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. If response is inadequate after six months, an increase to 9 mg (3 mg three times daily) may be tolerated. If response remains inadequate after a three-month trial of 9 mg daily, RIDAURA therapy should be discontinued. Safety at dosages exceeding 9 mg daily has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-10.2"></a><p></p>
<h2>Transferring from Injectable Gold:</h2>
<p class="First">In controlled clinical studies, patients on injectable gold have been transferred to RIDAURA (auranofin) by discontinuing the injectable agent and starting oral therapy with RIDAURA, 6 mg daily. When patients are transferred to RIDAURA, they should be informed of its adverse reaction profile, in particular the gastrointestinal reactions. (See <a href="#s17">PRECAUTIONS— Information for Patients</a>.) At six months, control of disease activity of patients transferred to RIDAURA and those maintained on the injectable agent was not different. Data beyond six months are not available.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s32"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Capsules, containing 3 mg auranofin, in bottles of 60.</p>
<p>NDC 65483-093-06</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s33"></a><a name="section-11.1"></a><p></p>
<h2>STORAGE AND HANDLING</h2>
<p class="First">Store between 15° and 30°C (59° and 86°F). Dispense in a tight, light-resistant container.</p>
<p>REVISED January 2011</p>
<p>©2007 Prometheus Laboratories Inc.<br> All rights reserved.</p>
<p>
RIDAURA is a registered trademark of Prometheus Laboratories Inc.
</p>
<p>
Manufactured for: <br><span class="Bold">Prometheus Laboratories Inc.<br></span>San Diego, CA 92121-4203</p>
<p>RI002E</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s34"></a><a name="section-12"></a><p></p>
<p class="First">Principal Display Panel – 3 mg Bottle Label
</p>
<p>3 mg      NDC 65483-093-06
</p>
<p>Ridaura<span class="Sup">®</span><br>Auranofin Capsules
</p>
<p>60 Capsules
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel – 3 mg Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&amp;name=rid01-0003-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIDAURA 		
					</strong><br><span class="contentTableReg">auranofin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65483-093</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>auranofin</strong> (auranofin) </td>
<td class="formItem">auranofin</td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cetylpyridinium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C Red No. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Red No. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RIDAURA
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65483-093-06</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018689</td>
<td class="formItem">04/24/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Prometheus Laboratories Inc.
							(967000860)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon, Inc., Toronto Region Operations</td>
<td class="formItem"></td>
<td class="formItem">240769596</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon, Inc., Burlington Century Operations</td>
<td class="formItem"></td>
<td class="formItem">259484350</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6008addc-7f8e-45bb-8aec-54dd54a788ac</div>
<div>Set id: 05c34ddf-a0f7-4267-83f5-d02be3defc37</div>
<div>Version: 3</div>
<div>Effective Time: 20111215</div>
</div>
</div> <div class="DistributorName">Prometheus Laboratories Inc.</div></p>
</body></html>
